- Home
- OTLK vs TPCS Comparison
OTLK vs TPCS Comparison
Compare OTLK & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- TPCS
- Stock Information
- Founded
- OTLK 2010
- TPCS 1956
- Country
- OTLK United States
- TPCS United States
- Employees
- OTLK N/A
- TPCS N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- TPCS Metal Fabrications
- Sector
- OTLK Health Care
- TPCS Industrials
- Exchange
- OTLK Nasdaq
- TPCS Nasdaq
- Market Cap
- OTLK 48.3M
- TPCS 51.4M
- IPO Year
- OTLK 2016
- TPCS N/A
- Fundamental
- Price
- OTLK $0.93
- TPCS $5.42
- Analyst Decision
- OTLK Buy
- TPCS
- Analyst Count
- OTLK 5
- TPCS 0
- Target Price
- OTLK $8.50
- TPCS N/A
- AVG Volume (30 Days)
- OTLK 7.8M
- TPCS 78.2K
- Earning Date
- OTLK 08-14-2025
- TPCS 08-21-2025
- Dividend Yield
- OTLK N/A
- TPCS N/A
- EPS Growth
- OTLK N/A
- TPCS N/A
- EPS
- OTLK N/A
- TPCS N/A
- Revenue
- OTLK $1,505,322.00
- TPCS $33,424,000.00
- Revenue This Year
- OTLK N/A
- TPCS N/A
- Revenue Next Year
- OTLK $484.88
- TPCS N/A
- P/E Ratio
- OTLK N/A
- TPCS N/A
- Revenue Growth
- OTLK N/A
- TPCS 3.78
- 52 Week Low
- OTLK $0.79
- TPCS $2.05
- 52 Week High
- OTLK $8.32
- TPCS $6.25
- Technical
- Relative Strength Index (RSI)
- OTLK 31.89
- TPCS 55.95
- Support Level
- OTLK $0.82
- TPCS $5.10
- Resistance Level
- OTLK $0.98
- TPCS $5.82
- Average True Range (ATR)
- OTLK 0.27
- TPCS 0.36
- MACD
- OTLK -0.15
- TPCS -0.06
- Stochastic Oscillator
- OTLK 5.25
- TPCS 58.76
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.